Which has stronger earnings & valuation, PFE or VTRS?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.36 $7.77B $1.31 19.81 Viatris $14.30B 1.28 -$3.51B -$0.26 N/A

Is PFE or VTRS more profitable?

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -2.04%. Pfizer's return on equity of 19.44% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Viatris -2.04% 19.04% 7.62%

Does the media refer more to PFE or VTRS?

In the previous week, Pfizer had 79 more articles in the media than Viatris. MarketBeat recorded 83 mentions for Pfizer and 4 mentions for Viatris. Pfizer's average media sentiment score of 1.08 beat Viatris' score of 0.90 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 66 Very Positive mention(s) 8 Positive mention(s) 1 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ARGX or VTRS?

argenex has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.06 $1.29B $22.46 39.73 Viatris $14.30B 1.28 -$3.51B -$0.26 N/A

Is ARGX or VTRS more profitable?

argenex has a net margin of 31.31% compared to Viatris' net margin of -2.04%. argenex's return on equity of 44.37% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Viatris -2.04% 19.04% 7.62%

Does the media prefer ARGX or VTRS?

In the previous week, argenex had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for argenex and 4 mentions for Viatris. argenex's average media sentiment score of 0.90 beat Viatris' score of 0.90 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VTRS or TAK?

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 11.25%. Given Viatris' higher possible upside, equities analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to VTRS or TAK?

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Takeda Pharmaceutical and 4 mentions for Viatris. Viatris' average media sentiment score of 0.90 beat Takeda Pharmaceutical's score of 0.47 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TEVA or VTRS?

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 4 mentions for Viatris. Teva Pharmaceutical Industries' average media sentiment score of 1.23 beat Viatris' score of 0.90 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VTRS or RVMD?

In the previous week, Revolution Medicines had 6 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Revolution Medicines and 4 mentions for Viatris. Revolution Medicines' average media sentiment score of 1.46 beat Viatris' score of 0.90 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viatris (VTRS) Competitors

$15.73 -0.31 (-1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$16.01 +0.28 (+1.81%)

As of 07:50 PM Eastern

Compare

VTRS vs. PFE, ARGX, TAK, TEVA, and RVMD

Should you buy Viatris stock or one of its competitors? MarketBeat compares Viatris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viatris include Pfizer (PFE), argenex (ARGX), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.

How does Viatris compare to Pfizer?

Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Pfizer has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.6%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.1%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -184.6% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -2.04%. Pfizer's return on equity of 19.44% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Viatris	-2.04%	19.04%	7.62%

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.36	$7.77B	$1.31	19.81
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A

Pfizer presently has a consensus price target of $28.82, suggesting a potential upside of 11.08%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 11.25%. Given Viatris' stronger consensus rating and higher probable upside, analysts plainly believe Viatris is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Pfizer had 79 more articles in the media than Viatris. MarketBeat recorded 83 mentions for Pfizer and 4 mentions for Viatris. Pfizer's average media sentiment score of 1.08 beat Viatris' score of 0.90 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	66 Very Positive mention(s)	8 Positive mention(s)	1 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pfizer beats Viatris on 15 of the 20 factors compared between the two stocks.

How does Viatris compare to argenex?

argenex (NASDAQ:ARGX) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, argenex had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for argenex and 4 mentions for Viatris. argenex's average media sentiment score of 0.90 beat Viatris' score of 0.90 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

argenex has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.06	$1.29B	$22.46	39.73
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A

60.3% of argenex shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

argenex presently has a consensus target price of $1,019.50, suggesting a potential upside of 14.26%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 11.25%. Given argenex's stronger consensus rating and higher probable upside, equities analysts plainly believe argenex is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

argenex has a net margin of 31.31% compared to Viatris' net margin of -2.04%. argenex's return on equity of 44.37% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Viatris	-2.04%	19.04%	7.62%

Summary

argenex beats Viatris on 14 of the 17 factors compared between the two stocks.

How does Viatris compare to Takeda Pharmaceutical?

Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Takeda Pharmaceutical and 4 mentions for Viatris. Viatris' average media sentiment score of 0.90 beat Takeda Pharmaceutical's score of 0.47 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. Viatris pays out -184.6% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 11.25%. Given Viatris' higher possible upside, equities analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

79.9% of Viatris shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Takeda Pharmaceutical has a net margin of 4.31% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
Takeda Pharmaceutical	$28.32B	1.73	$1.27B	$0.39	39.50

Summary

Viatris beats Takeda Pharmaceutical on 10 of the 18 factors compared between the two stocks.

How does Viatris compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.17	$1.41B	$1.33	24.50
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Viatris' net margin of -2.04%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Viatris	-2.04%	19.04%	7.62%

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 4 mentions for Viatris. Teva Pharmaceutical Industries' average media sentiment score of 1.23 beat Viatris' score of 0.90 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, suggesting a potential upside of 28.21%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 11.25%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Viatris on 14 of the 16 factors compared between the two stocks.

How does Viatris compare to Revolution Medicines?

Viatris (NASDAQ:VTRS) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Revolution Medicines has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
Revolution Medicines	$11.58M	2,896.54	-$1.13B	-$7.07	N/A

79.9% of Viatris shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Revolution Medicines	N/A	-83.22%	-59.06%

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 11.25%. Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 21.58%. Given Viatris' higher possible upside, equities research analysts plainly believe Viatris is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Revolution Medicines had 6 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Revolution Medicines and 4 mentions for Viatris. Revolution Medicines' average media sentiment score of 1.46 beat Viatris' score of 0.90 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Viatris on 12 of the 17 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTRS vs. The Competition

Export

Metric	Viatris	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.68B	$8.76B	$6.52B	$12.23B
Dividend Yield	2.99%	1.72%	2.67%	5.71%
P/E Ratio	-60.50	19.13	20.92	22.20
Price / Sales	1.28	17.32	524.00	109.99
Price / Cash	2.17	92.85	43.94	55.48
Price / Book	1.23	5.55	10.63	6.61
Net Income	-$3.51B	$177.20M	$3.57B	$337.89M
7 Day Performance	-0.25%	2.80%	1.42%	1.65%
1 Month Performance	-4.55%	9.55%	2.01%	3.10%
1 Year Performance	79.57%	4.85%	27.77%	29.69%

Viatris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTRS Viatris	3.1628 of 5 stars	$15.73 -1.9%	$17.50 +11.3%	+78.4%	$18.68B	$14.30B	N/A	30,000
PFE Pfizer	3.8593 of 5 stars	$25.66 -1.5%	$28.82 +12.4%	+6.7%	$148.41B	$62.58B	19.58	75,000	Positive News
ARGX argenex	4.0526 of 5 stars	$882.41 -1.0%	$1,019.50 +15.5%	+59.4%	$55.43B	$4.25B	39.29	1,863
TAK Takeda Pharmaceutical	3.4686 of 5 stars	$15.78 +1.1%	N/A	+3.8%	$49.65B	$28.32B	40.45	47,455
TEVA Teva Pharmaceutical Industries	4.6495 of 5 stars	$33.24 -2.8%	$41.78 +25.7%	+87.9%	$39.31B	$17.26B	24.99	33,950	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTRS) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viatris (VTRS) Competitors

VTRS vs. PFE, ARGX, TAK, TEVA, and RVMD

How does Viatris compare to Pfizer?

Summary

How does Viatris compare to argenex?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Summary

How does Viatris compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viatris (VTRS) Competitors

VTRS vs. PFE, ARGX, TAK, TEVA, and RVMD

How does Viatris compare to Pfizer?

Which has more risk and volatility, PFE or VTRS?

Do insiders and institutionals hold more shares of PFE or VTRS?

Is PFE or VTRS a better dividend stock?

Is PFE or VTRS more profitable?

Which has stronger earnings & valuation, PFE or VTRS?

Do analysts recommend PFE or VTRS?

Does the media refer more to PFE or VTRS?

Summary

How does Viatris compare to argenex?

Does the media prefer ARGX or VTRS?

Which has more volatility & risk, ARGX or VTRS?

Which has preferable earnings and valuation, ARGX or VTRS?

Do institutionals and insiders have more ownership in ARGX or VTRS?

Do analysts recommend ARGX or VTRS?

Is ARGX or VTRS more profitable?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Which has more volatility and risk, VTRS or TAK?

Does the media refer more to VTRS or TAK?

Is VTRS or TAK a better dividend stock?

Do analysts prefer VTRS or TAK?

Do insiders and institutionals hold more shares of VTRS or TAK?

Is VTRS or TAK more profitable?

Which has better earnings & valuation, VTRS or TAK?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Do insiders & institutionals have more ownership in TEVA or VTRS?

Which has higher valuation & earnings, TEVA or VTRS?

Is TEVA or VTRS more profitable?

Does the media favor TEVA or VTRS?

Do analysts recommend TEVA or VTRS?

Which has more volatility and risk, TEVA or VTRS?

Summary

How does Viatris compare to Revolution Medicines?

Which has more risk and volatility, VTRS or RVMD?

Which has higher earnings & valuation, VTRS or RVMD?

Do insiders and institutionals hold more shares of VTRS or RVMD?

Is VTRS or RVMD more profitable?

Do analysts recommend VTRS or RVMD?

Does the media refer more to VTRS or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools